IL6 and cancer: Next, to identify the responsible factors activating NF-κB, we have treated cells (EP and LP) with MDSC supernatant in presence/absence of IL-6, IL-10 and IL-1β neutralizing antibodies, keeping untreated cancer cells as a control.